Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.
Saved in:
| Title: | Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. |
|---|---|
| Authors: | Jain N; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Hartert K; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA., Tadros S; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA., Fiskus W; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Havranek O; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ma MCJ; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Bouska A; Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA., Heavican T; Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA., Kumar D; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Deng Q; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Moore D; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA., Pak C; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Liu CL; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Gentles AJ; Department of Radiology, Stanford University, Stanford, CA 94305, USA., Hartmann E; Institute of Pathology, University of Würzburg, Würzburg 97080, Germany.; Comprehensive Cancer Center Mainfranken, Wurzburg 97080, Germany., Kridel R; Princess Margaret Cancer Center, University of Toronto, Toronto, ON M5G 2C4, Canada., Smedby KE; Department of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm SE-171 76, Sweden., Juliusson G; Department of Laboratory Medicine, Stem Cell Center, Lund University, Lund SE-221 00, Sweden., Rosenquist R; Department of Molecular Medicine and Surgery, Karolinska Universitetssjukhuset, Stockholm SE-171 76, Sweden., Gascoyne RD; Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada., Rosenwald A; Institute of Pathology, University of Würzburg, Würzburg 97080, Germany.; Comprehensive Cancer Center Mainfranken, Wurzburg 97080, Germany., Giancotti F; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Neelapu SS; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Westin J; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Vose JM; Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA., Lunning MA; Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA., Greiner T; Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA., Rodig S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Iqbal J; Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA., Alizadeh AA; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA., Davis RE; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Bhalla K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Green MR; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. mgreen5@mdanderson.org.; Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. |
| Source: | Science translational medicine [Sci Transl Med] 2019 Jun 19; Vol. 11 (497). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1946-6242 |
|---|---|
| DOI: | 10.1126/scitranslmed.aav5599 |
